Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaneck Biotech ETF (NQ: BBH )

162.34 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaneck Biotech ETF

VanEck Announces Year-End Distributions for VanEck Equity ETFs
From VanEck
Via Business Wire
Time For Gilead Sciences-Heavy ETFs?
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of... 
Via Benzinga
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
Via Benzinga
VanEck Launches Robotics ETF (IBOT)
From VanEck
Via Business Wire
US Judge Weighs Nationwide Ban On Abortion Pills
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is... 
Via Benzinga
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
Via Benzinga
3 Best Funds for Aggressive Investors
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
Progenity Is Unlikely to Live Up to Its IPO Hype
Progenity went public in June 2020. Eighteen months later, PROG stock has lost 83% of its value. Is there any hope for this fading biotech? 
Via InvestorPlace
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
With an economic hurricane on the horizon, investors are searching for alternative investment paths and profitable places to invest in. 
Via InvestorPlace
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see... 
Via Talk Markets
Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone
After the formidable run, NVAX stock has come under significant pressure, but between its pipeline and its Covid vaccine, it is a dip buy. 
Via InvestorPlace
Take A Look At The Top-Performing Biotech ETFs YTD
The biotechnology sector has been grabbing the headlines on the new coronavirus vaccine and drug-related updates. The space has also kept its promise of generating returns, with the Nasdaq... 
Via Talk Markets
Exposures COVID-19
Biotech ETFs To Benefit From Latest Booster Update
Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from... 
Via Talk Markets
Exposures COVID-19
ETF Investing Areas to Consider for August
There is no doubt that the second-quarter 2021 earnings season is going strong. 
Via Talk Markets
Moderna ETFs To Rise On Positive COVID-19 Vaccine Updates
The competition to come up with a vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to... 
Via Talk Markets
Exposures COVID-19
5 Top ETFs With Exposure To Biogen
Here is a look at five ETFs with large exposure to Biogen shares. 
Via Talk Markets
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
Exposures Product Safety
Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines
The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from... 
Via Talk Markets
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Stock Moves After Q1 Print: Technical Levels For The COVID-19 Vaccine Play
Moderna Inc. (NASDAQ: MRNA) shares gapped down Thursday and have since gained back some ground. Moderna reported first-quarter earnings Thursday of $2.84 per share, beating the... 
Via Benzinga
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.